Stories about National Institutes of Health

Subscribe to National Institutes of Health

12.04.2021 – 08:27

Grünenthal Group
Grünenthal acquires Mestex AG and its Phase-III-ready investigational medicine MTX-071 for the treatment of pain associated with osteoarthritis of the knee

Aachen, Germany (ots) - - With the acquisition of Mestex AG, Grünenthal secures global rights for an attractive late-stage asset that could offer an innovative therapy option for millions of patients affected by pain related to osteoarthritis of the knee. - MTX-071 (resiniferatoxin) is a highly potent Transient ...

more
02.03.2021 – 14:36

B. Braun Melsungen AG

2
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb®

more
18.02.2021 – 17:05

Technische Universität München
Artificial intelligence deciphers genetic instructions: Deep learning algorithms reveal the rules of gene regulation

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center Phone: +49 89 289 10510 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36455/ High resolution image: https://mediatum.ub.tum.de/1596818 NEWS RELEASE Artificial intelligence ...

more
12.02.2021 – 09:43

Technische Universität München
New synthetic peptides could attenuate atherosclerosis

Corporate Communications Center phone: +49 8161 5403 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/36446/ NEWS RELEASE New synthetic peptides could attenuate atherosclerosis Synthetic “mini” receptors block atherosclerosis Atherosclerosis, a lipid-triggered chronic inflammatory disease of our arteries, is the main cause of strokes and ...

more
31.03.2020 – 18:00

Novo Nordisk A/S
Saxenda® Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda® (liraglutide 3.0 mg) in adolescents (aged ...

more
26.03.2020 – 18:22

Elastrin Therapeutics
Elastrin Therapeutics develops new approach against "Inflammatory Storm" that kills most Corona patients

Greenville South Carolina (ots) - A previously untested approach to preventing the most severe outcomes of lung diseases, including COVID-19, has been developed by Elastrin Therapeutics based on targeting damaged elastic fiber that leads to impaired lung function. The company has developed the world's first ...

more
01.10.2019 – 19:39

Novo Nordisk A/S
Novo Nordisk and Noom to partner around digital health solutions to help people with obesity lose weight and keep it off

Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk, a global healthcare company, and Noom, a leading behaviour change company, today announced a collaboration on digital health solutions focusing on weight management and education, with the aim of improving the lives of people living with obesity. The collaboration ...

more
28.03.2019 – 14:30

Mundipharma EDO
Mundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer

Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...

more

1